These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14981994)

  • 1. Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature.
    Gadducci A; Cosio S; Fanucchi A; Nardini V; Roncella M; Conte PF; Genazzani AR
    Anticancer Res; 2003; 23(6D):5225-9. PubMed ID: 14981994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P; Biswas N; Coleman M
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma.
    Hubalek M; Smekal-Schindelwig C; Zeimet AG; Sergi C; Brezinka C; Mueller-Holzner E; Marth C
    Arch Gynecol Obstet; 2007 Aug; 276(2):179-83. PubMed ID: 17342499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.
    Ring AE; Smith IE; Jones A; Shannon C; Galani E; Ellis PA
    J Clin Oncol; 2005 Jun; 23(18):4192-7. PubMed ID: 15961766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
    Andreadis C; Charalampidou M; Diamantopoulos N; Chouchos N; Mouratidou D
    Gynecol Oncol; 2004 Oct; 95(1):252-5. PubMed ID: 15385141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.
    Sood AK; Shahin MS; Sorosky JI
    Gynecol Oncol; 2001 Dec; 83(3):599-600. PubMed ID: 11733979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
    De Giorgi U; Giannini M; Frassineti L; Kopf B; Palazzi S; Giovannini N; Zumaglini F; Rosti G; Emiliani E; Marangolo M
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1165-9. PubMed ID: 16682141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
    Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breast cancer during pregnancy--a case report].
    Matsunoki A; Yoshino H; Takayanagi T; Kadoya S; Kotake M; Ishiguro K; Kurokawa M; Morita K; Bandou H; Yamada C; Yamada T
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):991-3. PubMed ID: 18633231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
    Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
    Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
    Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
    Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
    Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
    Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
    Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
    Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
    Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
    Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of locally advanced breast cancer successfully treated with FEC (100) followed by weekly paclitaxel].
    Tokunaga Y; Takahashi K; Saito T
    Gan To Kagaku Ryoho; 2005 Sep; 32(9):1307-9. PubMed ID: 16184929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.